Beximco Pharmaceuticals Limited Sponsored GDR RegS ( (GB:BXP) ) has shared an announcement.
Beximco Pharmaceuticals Limited has announced an update regarding a legal matter involving the Bangladesh Securities and Exchange Commission (BSEC) and the Supreme Court of Bangladesh. The Supreme Court’s Appellate Division has overturned a previous High Court Stay Order related to the BSEC’s proposal to appoint nine new independent non-executive directors to Beximco’s Board. The final decision on these appointments is pending further High Court proceedings and due diligence for UK regulatory compliance. This development could significantly impact the company’s governance structure, potentially influencing its strategic direction and stakeholder relations.
More about Beximco Pharmaceuticals Limited Sponsored GDR RegS
Beximco Pharmaceuticals Limited, based in Bangladesh, is a prominent manufacturer and exporter of generic medicines. Established in 1976, the company is dedicated to providing access to contemporary medicines worldwide. Its extensive product range includes tablets, capsules, liquids, semi-solids, and various inhalers, among others. Beximco Pharma also engages in contract manufacturing for multinational and global generic pharmaceutical companies. The company operates state-of-the-art manufacturing facilities certified by global regulatory authorities and has a presence in over 50 countries, employing more than 6,000 people.
YTD Price Performance: -1.28%
Average Trading Volume: 33,754
Technical Sentiment Consensus Rating: Buy
For a thorough assessment of BXP stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com